Campaigns. It is important that I continue to know the strength of feeling on an issue and I prefer to respond to every inquiry, but the sheer size of campaign correspondence means that it is hard to justify to the tax payer the cost and time taken for individual written replies, so regrettably I will no longer reply to every item of campaign correspondence.  I will  post a response to the campaign on the "Responses to campaigns" page of my website.

I am sorry to do this, as it is rather impersonal, but can see no other way of maintaining a good service for all my constituents unless I approach campaigns this way.


08 FEB 2018

MS and Cannabis

Thank you for taking the time to email me.

I read your comments with interest and understand you would like to see medicinal cannabis available to those suffering with MS. I appreciate your stance on this matter and hope the following information on this topic from the Department of Health reassuring:

Cannabis in its raw form is not recognised as having any medicinal purposes. The licensing regime for medicines is administered by the Medicines and Healthcare products Regulatory Agency (MHRA), which issues licences for medicines in the UK which have been tested for their safety, quality and efficacy.
A medicine derived from the cannabis plant, Sativex, has already been licenced for use in the treatment of spasticity due to multiple sclerosis (MS). The MHRA is open to considering other licence applications for medicines containing cannabinoids should such products be developed. You may be pleased to hear that the Minister for Safeguarding, Vulnerability and Crime has recently written to and met with the Parliamentary under Secretary of State for Public Health and Primary Care to consider how to ensure cannabis-based medicines are available where appropriate.
In 2014, the National Institute for Health and Care Excellence (NICE) published its clinical guideline on the management of MS that does not recommend Sativex as a cost effective use of NHS resources. In the absence of positive guidance from NICE, it is for commissioners to make decisions on whether to fund this treatment based on an assessment of the available evidence.
There are people with chronic pain and debilitating illnesses who seek to alleviate their symptoms by using cannabis. Although such use is illicit, the Sentencing Council's guidelines on drug offences identify such circumstances as a potential mitigating factor.
The Government has no plans to legalise the recreational use of cannabis. The official advice from the Advisory Council on the Misuse of Drugs cites medical and scientific research showing that cannabis use has a number of adverse acute and chronic health effects, especially for people with mental health problems, and continues to present a significant public health issue.

Back to all posts